Title | Development and testing of a polygenic risk score for breast cancer aggressiveness. |
Publication Type | Journal Article |
Year of Publication | 2023 |
Authors | Shieh, Y, Roger, J, Yau, C, Wolf, DM, Hirst, GL, Swigart, LBrown, Huntsman, S, Hu, D, Nierenberg, JL, Middha, P, Heise, RS, Shi, Y, Kachuri, L, Zhu, Q, Yao, S, Ambrosone, CB, Kwan, ML, Caan, BJ, Witte, JS, Kushi, LH, Veer, Lvan 't, Esserman, LJ, Ziv, E |
Journal | NPJ Precis Oncol |
Volume | 7 |
Issue | 1 |
Pagination | 42 |
Date Published | 2023 May 15 |
ISSN | 2397-768X |
Abstract | Aggressive breast cancers portend a poor prognosis, but current polygenic risk scores (PRSs) for breast cancer do not reliably predict aggressive cancers. Aggressiveness can be effectively recapitulated using tumor gene expression profiling. Thus, we sought to develop a PRS for the risk of recurrence score weighted on proliferation (ROR-P), an established prognostic signature. Using 2363 breast cancers with tumor gene expression data and single nucleotide polymorphism (SNP) genotypes, we examined the associations between ROR-P and known breast cancer susceptibility SNPs using linear regression models. We constructed PRSs based on varying p-value thresholds and selected the optimal PRS based on model r in 5-fold cross-validation. We then used Cox proportional hazards regression to test the ROR-P PRS's association with breast cancer-specific survival in two independent cohorts totaling 10,196 breast cancers and 785 events. In meta-analysis of these cohorts, higher ROR-P PRS was associated with worse survival, HR per SD = 1.13 (95% CI 1.06-1.21, p = 4.0 × 10). The ROR-P PRS had a similar magnitude of effect on survival as a comparator PRS for estrogen receptor (ER)-negative versus positive cancer risk (PRS) Furthermore, its effect was minimally attenuated when adjusted for PRS, suggesting that the ROR-P PRS provides additional prognostic information beyond ER status. In summary, we used integrated analysis of germline SNP and tumor gene expression data to construct a PRS associated with aggressive tumor biology and worse survival. These findings could potentially enhance risk stratification for breast cancer screening and prevention. |
DOI | 10.1038/s41698-023-00382-z |
Alternate Journal | NPJ Precis Oncol |
PubMed ID | 37188791 |
PubMed Central ID | PMC10185660 |
Grant List | U01 CA195565 / CA / NCI NIH HHS / United States K08 CA237829 / CA / NCI NIH HHS / United States R01 CA129059 / CA / NCI NIH HHS / United States R01 CA105274 / CA / NCI NIH HHS / United States K24 CA169004 / CA / NCI NIH HHS / United States P01 CA210961 / CA / NCI NIH HHS / United States U01 CA196406 / CA / NCI NIH HHS / United States |